Medesis Pharma SA - Asset Resilience Ratio

Latest as of December 2023: -1.48%

Medesis Pharma SA (ALMDP) has an Asset Resilience Ratio of -1.48% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read ALMDP total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

€-28.50K

≈ $-33.32K USD Cash + Short-term Investments

Total Assets

€1.93 Million

≈ $2.25 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2018–2023)

This chart shows how Medesis Pharma SA's Asset Resilience Ratio has changed over time. See Medesis Pharma SA defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Liquid Assets Composition Over Time

This chart breaks down Medesis Pharma SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ALMDP asset base.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€-28.50K	-1.48%
Total Liquid Assets	€-28.50K	-1.48%

Asset Resilience Insights

Limited Liquidity: Medesis Pharma SA maintains only -1.48% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Medesis Pharma SA Industry Peers by Asset Resilience Ratio

Compare Medesis Pharma SA's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Celltrion Inc KO:068270	Biotechnology	0.56%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Summit Therapeutics PLC NASDAQ:SMMT	Biotechnology	75.98%
Immunovant Inc NASDAQ:IMVT	Biotechnology	98.50%
Abivax SA PA:ABVX	Biotechnology	2.34%
Protagonist Therapeutics Inc NASDAQ:PTGX	Biotechnology	65.90%
Disc Medicine Inc. NASDAQ:IRON	Biotechnology	85.48%
Vericel Corp Ord NASDAQ:VCEL	Biotechnology	7.67%

Annual Asset Resilience Ratio for Medesis Pharma SA (2018–2023)

The table below shows the annual Asset Resilience Ratio data for Medesis Pharma SA.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2023-12-31	-1.48%	€-28.50K ≈ $-33.32K	€1.93 Million ≈ $2.25 Million	-7.33pp
2018-12-31	5.85%	€95.00K ≈ $111.06K	€1.62 Million ≈ $1.90 Million	--

pp = percentage points

About Medesis Pharma SA

PA:ALMDP France Biotechnology

Market Cap

$2.11 Million

€1.80 Million EUR

Market Cap Rank

#30180 Global

#561 in France

Share Price

€0.35

Change (1 day)

+0.00%

52-Week Range

€0.35 - €0.35

All Time High

€16.80